cardiometabolic diseases

MannKind to Acquire scPharmaceuticals in Up to $360M Deal

2 weeks ago talkbio0Tagged Acquisition, cardiometabolic diseases, cardiorenal medicine, FDA-approved, FUROSCIX, MannKind, merger agreement, ReadyFlow Autoinjector, scPharmaceuticals, Tender

MannKind; scPharmaceuticals; acquisition; Furoscix; cardiorenal medicine; cardiometabolic diseases; FDA-approved infuser; ReadyFlow autoinjector; merger agreement; tender offer

Eli Lilly and Superluminal Ink $1.3B Pact Targeting GPCRs in Obesity, Cardiometabolic Diseases

4 weeks ago talkbio0Tagged Aortic Valve Insufficiency, cardiometabolic diseases, Eli, Eli Lilly, equity, GPCRs, Investments, MC4R, MC4R protein, human, milestones, Obesity, Partnership, Superluminal Medicines

Eli Lilly; Superluminal Medicines; GPCRs; obesity drugs; cardiometabolic diseases; AI drug discovery; MC4R; partnership; milestones; equity investment

Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines

3 months ago talkbio0Tagged biotech partnership, cardiometabolic diseases, Collaboration, Deep Apple, G-Protein-Coupled Receptors, Nordisk, Obesity, Oral Medicine, R&D, small molecule therapeutics, Target

Novo Nordisk; Deep Apple Therapeutics; cardiometabolic diseases; oral medicines; obesity; small molecule therapeutics; GPCR target; R&D collaboration; biotech partnership

Novo Nordisk and Septerna Forge $2.2B+ Collaboration on Oral Obesity and Diabetes Drugs

4 months ago talkbio0Tagged cardiometabolic diseases, Collaboration, Diabetes Mellitus, Non-Insulin-Dependent, G-Protein-Coupled Receptors, Gastric Inhibitory Polypeptide, Glucagon Receptor, Glucagon-Like Peptide 1, Nordisk, Obesity, oral drugs, Septerna, small molecule therapies

Novo Nordisk; Septerna; GPCR; oral drugs; obesity; type 2 diabetes; cardiometabolic diseases; GLP-1; GIP; glucagon receptors; small molecule therapies; collaboration; pharmaceuticals

Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships

7 months ago talkbio0Tagged AdvanCell, alpha therapies, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, MASH, OliX, Radiopharmaceuticals, strategic collaborations

Eli Lilly, AdvanCell, OliX Pharmaceuticals, targeted alpha therapies, radiopharmaceuticals, MASH, cardiometabolic diseases, strategic collaborations

Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies

7 months ago talkbio0Tagged AdvanCell, alpha therapies, Cancer Therapeutic Procedure, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, Interferes with, MASH, OliX, Radiopharmaceuticals, RNA

Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment

Novo Nordisk and Photys Therapeutics Collaborate on Novel Proximity-Based Therapeutics for Cardiometabolic Diseases

9 months ago talkbio0Tagged cardiometabolic diseases, Nordisk, PHICS, proximity-based, research collaboration, Technology

Novo Nordisk, Photys Therapeutics, Cardiometabolic diseases, Proximity-based therapeutics, PHICS technology, Research collaboration

AstraZeneca Advances in Obesity Market with ECC5004 Deal and Promising Clinical Data

10 months ago talkbio0Tagged AstraZeneca, cardiometabolic diseases, GLP-1RA, Obesity, Weight Loss

AstraZeneca, obesity, ECC5004, GLP-1RA, cardiometabolic diseases, weight loss market

Rivus Pharmaceuticals Unveils Promising Phase 2a Results for HU6 in Obesity-Related Heart Failure Patients

12 months ago talkbio0Tagged cardiometabolic diseases, CMAs, fat-selective weight loss, HU6, Mitochondria, obesity-related heart failure, Rivus Pharmaceuticals, uncoupling

HU6, Rivus Pharmaceuticals, obesity-related heart failure, fat-selective weight loss, controlled metabolic accelerators (CMAs), mitochondrial uncoupling, cardiometabolic diseases.

Novo Nordisk Partners with NanoVation in $600M Deal for Advanced Genetic Medicine Delivery

12 months ago talkbio0Tagged cardiometabolic diseases, Genetic Medicine, Hereditary Diseases, Lipid Nanoparticles, NanoVation, Nordisk, Technology

Novo Nordisk, NanoVation Therapeutics, Genetic Medicine, Lipid Nanoparticle (LNP) Technology, Cardiometabolic Diseases, Rare Genetic Disorders